The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group ...

AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, ...

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a ...

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform.